- Market Capitalization, $K 60,743
- Shares Outstanding, K 26,070
- Annual Sales, $ 5,990 K
- Annual Income, $ -12,670 K
- 60-Month Beta 1.96
- Price/Sales 10.31
- Price/Cash Flow N/A
- Price/Book N/A
|Period||Period Low||Period High||Performance|
| || |
-0.46 (-16.49%)since 09/18/19
| || |
-0.42 (-15.27%)since 07/18/19
| || |
-0.25 (-9.69%)since 10/18/18
Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced the U.S. Food and Drug Administration (FDA) has approved SECUADO (R) (asenapine) transdermal...
Acne vulgaris is a common skin disease characterized by blackheads, whiteheads, papules, and pustules on the face, neck, back, and chest. Although the condition is more prevalent in adolescent population,...
Novan, Inc. ("the Company" or "Novan") (Nasdaq:NOVN) today announced that the Company's Phase 2 molluscum study, designed to evaluate topical nitric oxide product candidate SB206 for the treatment of molluscum...
Noven Pharmaceuticals, Inc. today announced its decision to appoint Dr. Naruhito Higo as Chief Executive Officer effective October 1, 2019, succeeding Jeff Mihm who has tendered his resignation. Noven...
Novan, Inc. ("the Company" or "Novan") (Nasdaq:NOVN) today announced that the Compensation Committee of Novan's Board of Directors granted stock options to purchase an aggregate of 25,000 shares of its...
Novan, Inc. ("the Company" or "Novan") (Nasdaq:NOVN) today announced that the Company has entered into a Common Stock Purchase Agreement (the "Agreement") of up to $25 million with Aspire Capital Fund,...
-- Underscores Company's preparation for potential NDA submission for SB206 in molluscum
Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that it will participate in the H.C. Wainwright 21st Annual Global Investment Conference in New York on Monday, September 9, 2019. Participation...
Iconic Therapeutics, a private biopharmaceutical company focused on novel therapeutics for serious diseases such as cancer and age-related macular degeneration (AMD), today announced that the Company has...
Novan, Inc. ("the Company" or "Novan") (Nasdaq:NOVN) today announced that the Company has executed a non-binding letter of intent (LOI) with a third party on its facility at 4105 Hopson Road in Morrisville,...